Is Egrifta (Tesamorelin) Legal in Missouri?

The Short Answer on Missouri Legality

Egrifta (tesamorelin) is legal in Missouri. It is a prescription medication with full FDA approval, and any Missouri-licensed prescriber with a valid DEA registration and an established patient-provider relationship may write an order for it. The state of Missouri does not impose any additional restrictions on tesamorelin beyond the federal framework that governs all prescription drugs. Missouri has not listed tesamorelin as a controlled substance under the Missouri Comprehensive Drug Control Act, RSMo Chapter 195.

The distinction that matters most for patients is the difference between obtaining brand-name Egrifta through a licensed pharmacy and obtaining compounded tesamorelin through a compounding pharmacy. Those two paths carry very different legal risks, detailed below.

Federal FDA Approval: What It Covers

Original Approval and the 2019 Reformulation

The FDA first approved tesamorelin (brand name Egrifta) on November 10, 2010, under NDA 022505, specifically for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. 1 The reformulated version, Egrifta SV, received approval in May 2019 and replaced the earlier formulation. 2

The approved dose is 2 mg administered by subcutaneous injection once daily into the abdomen. 3

What "FDA-Approved" Means for Missouri Patients

FDA approval means the drug met the statutory standards for safety and efficacy under 21 U.S.C. § 355. 4 Any licensed Missouri pharmacy can stock and dispense Egrifta SV against a valid prescription. The pharmacist does not need a special license beyond their standard Missouri Board of Pharmacy registration, and the patient does not need a special permit to possess or use it.

Off-label prescribing (for indications beyond HIV lipodystrophy, such as age-related growth hormone decline or body composition optimization) is also legal. The FDA regulates manufacturers, not the practice of medicine. Missouri's Medical Practice Act, RSMo § 334.100, gives licensed physicians broad discretion to prescribe approved medications for unlabeled uses. Off-label prescribing of tesamorelin is therefore lawful in Missouri, provided the prescriber documents clinical rationale, obtains informed consent, and follows the standard of care.

Missouri State-Level Legal Framework

Missouri Controlled Substances Act

Missouri's Comprehensive Drug Control Act (RSMo Chapter 195) mirrors the federal Controlled Substances Act schedules. Tesamorelin does not appear in any federal schedule (I through V) and does not appear in Missouri's state schedules. 5 This means no DEA Form 222 is required, no Schedule II triplicate prescriptions are required, and there are no state-mandated limits on days' supply for tesamorelin specifically.

Missouri Board of Pharmacy Rules

The Missouri Board of Pharmacy enforces 20 CSR 2220, which incorporates USP standards for sterile compounding. 6 Tesamorelin is a sterile injectable peptide, so any pharmacy compounding it must comply with USP 797 sterility standards, maintain appropriate beyond-use dating, and operate under a valid Missouri pharmacy license. The Board has authority to inspect, audit, and discipline pharmacies that produce substandard or illegally compounded products.

Missouri Telehealth Prescribing

Missouri HB 1682 (2018) and subsequent Medicaid telehealth expansions permit synchronous audio-video telehealth visits to establish a valid patient-provider relationship. 7 A prescriber may write a tesamorelin prescription following a telehealth encounter if the clinical evaluation meets Missouri's standard of care. Missouri does not require an in-person visit before prescribing tesamorelin, but prescribers must document that a proper history, physical assessment (or documented reason for waiver), and informed consent process occurred.

Compounding Tesamorelin: The Federal 503A/503B Divide

This section is where most patients and clinicians encounter confusion. Tesamorelin is FDA-approved, and that fact has direct consequences for compounding pharmacies.

503A Pharmacies (Traditional Compounding)

Under 21 U.S.C. § 503A, a traditional compounding pharmacy may prepare a drug product for an individual patient if: (1) the compound is not essentially a copy of a commercially available drug, (2) the active ingredient is on FDA's approved bulk substances list (the "503A bulks list") or is a component of an FDA-approved drug, and (3) the compounding is done pursuant to a valid prescription. 8

Tesamorelin is the active ingredient in an FDA-approved, commercially available drug (Egrifta SV). Compounding an essentially identical product under 503A is therefore legally precarious. The FDA's guidance on essentially-a-copy determinations states that a 503A pharmacy may not routinely compound a drug that is essentially a copy of a commercially available product. 9 Compounding tesamorelin at the same strength and route as Egrifta SV with no meaningful clinical difference would likely violate this restriction.

A 503A pharmacy could potentially argue a clinical difference (different concentration, different diluent volume, absence of a specific excipient the patient cannot tolerate), but the prescriber and pharmacist carry the legal burden of documenting that clinical rationale. Without it, the compound is vulnerable to FDA enforcement.

503B Outsourcing Facilities

503B outsourcing facilities operate under stricter FDA oversight: registration with the FDA, CGMP compliance, and no requirement for patient-specific prescriptions. 10 However, 503B facilities face the same "essentially a copy" restriction. The FDA's current enforcement policy does not formally place tesamorelin on the 503B bulk substances list, which means a 503B facility compounding bulk tesamorelin outside a specific patient clinical justification is operating in a legally gray zone and faces real enforcement risk. 11

Practical Takeaway for Missouri Patients

The safest legal path is: obtain a prescription from a Missouri-licensed provider, have it filled at a licensed pharmacy dispensing brand-name Egrifta SV, and use it for the FDA-approved indication or with documented off-label clinical rationale. Compounded tesamorelin is not categorically illegal in every scenario, but the legal protections are thinner than for the branded product, and patients should confirm with their prescriber and pharmacist that the compound meets 503A or 503B requirements before use.

Clinical Profile of Tesamorelin: What the Evidence Shows

Mechanism of Action

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates pulsatile release of endogenous growth hormone (GH), which in turn raises IGF-1 levels. 12 Unlike exogenous recombinant human GH (rhGH), tesamorelin preserves the physiologic feedback loop: elevated IGF-1 feeds back on the hypothalamus to limit GH secretion, reducing the risk of supraphysiologic IGF-1 elevations.

Key Trial Data for HIV Lipodystrophy

Two Phase 3 placebo-controlled trials (LIPO-010 and LIPO-011, combined N = 816) formed the basis of FDA approval. Tesamorelin 2 mg/day reduced visceral adipose tissue (VAT) by 17.8% versus 1.0% with placebo at 26 weeks (P<0.001). 13 The same trials showed a trunk-to-limb fat ratio improvement and patient-reported satisfaction with abdominal appearance. IGF-1 levels increased but remained within the normal reference range in most participants.

A 52-week extension study (N = 273) confirmed durability: patients maintained on tesamorelin preserved VAT reductions, while patients switched to placebo regained visceral fat within 12 weeks. 14

Off-Label Evidence: Age-Related GH Decline

Several investigator-initiated studies have examined tesamorelin in non-HIV populations. A randomized trial by Falutz et al. Published in the New England Journal of Medicine in 2010 showed tesamorelin reduced VAT by 18% in HIV patients, with a favorable safety profile over 26 weeks. 15 The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults notes that GHRH analogues "stimulate endogenous GH secretion and may offer an alternative to exogenous GH therapy in selected patients," though the guideline does not endorse routine off-label use for age-related decline. 16

A 2021 study in 152 cognitively normal older adults examined tesamorelin's effects on cognition and found that 20 weeks of treatment improved executive function scores compared to placebo (P<0.05), though the authors noted the need for larger confirmatory trials before clinical application. 17

Safety Signals to Document

The most common adverse effects reported in clinical trials include peripheral edema (17.8% vs. 5.6% placebo), arthralgia (13.4% vs. 5.6% placebo), and injection-site reactions. 3 Glucose metabolism: tesamorelin increases IGF-1, which can reduce insulin sensitivity. The FDA label carries a warning for patients with diabetes or glucose intolerance. 3 Prescribers should obtain a fasting glucose or HbA1c at baseline and recheck at 3 months. Tesamorelin is contraindicated in active malignancy and in patients with disruption of the hypothalamic-pituitary axis (e.g., from cranial irradiation or pituitary adenoma). 18

How to Get a Tesamorelin Prescription in Missouri

Step 1: Find a Qualified Prescriber

Missouri-licensed MDs, DOs, and advanced practice registered nurses (APRNs) with collaborative practice agreements may prescribe tesamorelin. Endocrinologists, infectious disease specialists managing HIV patients, and hormone-therapy-focused primary care physicians are the most common prescribers. Missouri does not require a specialist referral before a primary care physician prescribes tesamorelin. 19

Step 2: Clinical Evaluation

A complete evaluation should include: documentation of HIV status and confirmed visceral adiposity (for on-label use) or documented clinical rationale for off-label use, baseline IGF-1 level, fasting glucose or HbA1c, CBC, and a discussion of the contraindications listed above. The Endocrine Society recommends IGF-1 monitoring every 3 months during GH-stimulating therapy to ensure levels remain within age- and sex-adjusted normal ranges. 16

Step 3: Prescription and Dispensing

A written or electronically transmitted prescription is sent to a Missouri-licensed pharmacy. For Egrifta SV, most major specialty pharmacies and some mail-order pharmacies carry the product. Insurance coverage varies: for HIV-associated lipodystrophy, many commercial plans and Medicaid may cover Egrifta SV. The Theratechnologies patient-assistance program (EGRIFTAssist) is available for uninsured or underinsured patients. For off-label use, out-of-pocket pricing applies in most cases.

Step 4: Ongoing Monitoring

After 3 months of therapy, the prescriber should reassess VAT reduction (clinically or by DEXA/CT), recheck IGF-1 and fasting glucose, and confirm the absence of emerging adverse effects. The FDA label states: "The continued use of Egrifta SV should be evaluated based on the response and tolerance of the patient." 3

Tesamorelin vs. Other Peptides: Legal Context

Several peptides used in similar "body composition optimization" contexts sit in very different legal positions. Understanding the contrast helps explain why tesamorelin is more legally accessible than many alternatives.

Sermorelin (GHRH 1-29) was an FDA-approved drug (Geref) that was voluntarily withdrawn from the U.S. Market in 2008. Because sermorelin is no longer commercially available, it can be compounded under 503A provided the active ingredient meets FDA bulk substance criteria, though its regulatory pathway is more ambiguous. 20

CJC-1295 and ipamorelin have never received FDA approval and are not on the 503A or 503B bulk substances list. The FDA has issued multiple warning letters to compounding pharmacies producing these peptides, stating they are not generally recognized as safe (GRAS) for compounding. 21

Tesamorelin's FDA approval makes it the legally cleanest option among GHRH-class peptides for Missouri patients.

Insurance, Cost, and Access in Missouri

Egrifta SV carries a list price exceeding $8,000 per month. For HIV-associated lipodystrophy, Missouri Medicaid (MO HealthNet) may cover the drug under prior authorization with documented HIV diagnosis and VAT measurement. Commercial payers generally require step therapy documentation. 22

For off-label prescriptions (the majority of anti-aging or body-composition use cases), coverage is rarely available. Patients should verify benefits before filling. Theratechnologies' co-pay assistance program can reduce out-of-pocket costs to as low as $0/month for commercially insured patients who qualify.

The cost difference between branded Egrifta SV and compounded tesamorelin can be substantial, but the legal risks of compounded versions (described above) should be weighed against the cost savings. A prescriber who documents a legitimate clinical reason (e.g., patient allergy to an excipient in Egrifta SV) may support a 503A compound with a stronger legal basis than a prescriber who orders the compound solely because it is less expensive.